Small Molecule Inhibitors of BRAF in Clinical Trials

Bioorg Med Chem Lett. 2012 Jan 15;22(2):789-92. doi: 10.1016/j.bmcl.2011.11.060. Epub 2011 Dec 3.

Abstract

Over the last few years, BRAF has emerged as a validated target in melanoma. This review summarises recent advances in the development of BRAF inhibitors, focussing on agents that have been assessed clinically.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic*
  • Humans
  • Melanoma / drug therapy*
  • Melanoma / metabolism
  • Molecular Weight
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / pharmacology*
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins B-raf / metabolism
  • Structure-Activity Relationship

Substances

  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins B-raf